Prognostic significance of inflammation-related and electrolyte laboratory variables in patients with malignant pleural mesothelioma
暂无分享,去创建一个
[1] B. Dong,et al. Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies , 2021, Experimental Hematology & Oncology.
[2] J. V. van Meerbeeck,et al. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis , 2021, European Respiratory Review.
[3] Letter to the Editor: Comment on 'Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions'. , 2021, Lung Cancer.
[4] W. Richards,et al. Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] S. Montefort,et al. The association between pleural fluid exposure and survival in pleural mesothelioma. , 2021, Chest.
[6] M. Johansson,et al. Systemic inflammation markers and cancer incidence in the UK Biobank , 2021, European Journal of Epidemiology.
[7] Y. Lacasse,et al. Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions. , 2021, Lung cancer.
[8] B. Ghanim,et al. Biomarkers for Malignant Pleural Mesothelioma—A Novel View on Inflammation , 2021, Cancers.
[9] C. Meristoudis,et al. Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting , 2021, Acta oncologica.
[10] D. Sugarbaker,et al. Pleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma , 2020, Annals of surgery.
[11] M. Clerici,et al. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. , 2020, Lung cancer.
[12] M. Balancin,et al. An integrative histopathologic clustering model based on immuno‐matrix elements to predict the risk of death in malignant mesothelioma , 2020, Cancer medicine.
[13] S. Chari,et al. Peripheral blood monocyte counts are elevated in the pre-diagnostic phase of pancreatic cancer: A population based study. , 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[14] Y. Doki,et al. Peri-operative monocyte count is a marker of poor prognosis in gastric cancer: increased monocytes are a characteristic of myeloid-derived suppressor cells , 2019, Cancer Immunology, Immunotherapy.
[15] S. Su,et al. The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma , 2019, Oncology Research and Treatment.
[16] J. Zucman‐Rossi,et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications , 2019, Nature Communications.
[17] Huy Q. Dinh,et al. Monocyte heterogeneity and functions in cancer , 2019, Journal of leukocyte biology.
[18] Dongliang Yang,et al. Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma , 2019, Gastroenterology research and practice.
[19] Wei-min Li,et al. High postoperative monocyte indicates inferior Clinicopathological characteristics and worse prognosis in lung adenocarcinoma or squamous cell carcinoma after lobectomy , 2018, BMC Cancer.
[20] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[21] E. Morii,et al. Peripheral blood monocyte count reflecting tumor‐infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens , 2017, The Prostate.
[22] G. Thomas,et al. Evaluating the effect of immune cells on the outcome of patients with mesothelioma , 2017, British Journal of Cancer.
[23] J. Aerts,et al. Novel insights into mesothelioma biology and implications for therapy , 2017, Nature Reviews Cancer.
[24] N. Hens,et al. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma , 2017, Oncoimmunology.
[25] G. Reid,et al. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma , 2016, Molecular Cancer.
[26] N. Le Stang,et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. , 2016, Human pathology.
[27] M. Zauderer,et al. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[28] Y. Maehara,et al. Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. , 2015, Journal of thoracic disease.
[29] N. Maskell,et al. Individualised management of malignant pleural effusion. , 2015, The Lancet. Respiratory medicine.
[30] N. Pavlakis,et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales , 2014, British Journal of Cancer.
[31] J. Creaney,et al. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma , 2013, British Journal of Cancer.
[32] L. Mutti,et al. Epigallocatechin-3-gallate induces mesothelioma cell death via H2O2—dependent T-type Ca2+ channel opening , 2012, Journal of cellular and molecular medicine.
[33] Y. Takeshima,et al. National survey of malignant mesothelioma and asbestos exposure in Japan , 2012, Cancer science.
[34] R. Ramakrishnan,et al. Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[35] D. Sugarbaker,et al. Circulating and tumor‐infiltrating myeloid cells predict survival in human pleural mesothelioma , 2011, Cancer.
[36] D. Klippenstein,et al. Malignant pleural mesothelioma after household exposure to asbestos. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] P. Allavena,et al. Role of tumor-associated macrophages in tumor progression and invasion , 2006, Cancer and Metastasis Reviews.
[38] H. Hammad,et al. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses , 2006, European Respiratory Journal.
[39] S. Leeder,et al. A population based study , 1993, The Medical journal of Australia.
[40] D. McMillan,et al. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. , 2010, Future oncology.